November 28, 2018 Press release - Non-regulatory Targovax is invited to present at upcoming investor and industry conferences
October 26, 2018 Press release - Regulatory Targovax ASA: Announcement of third quarter 2018 financial results
October 15, 2018 Press release - Non-regulatory Targovax reports encouraging disease-free survival (DFS) data from TG01 trial in resected pancreatic cancer
October 12, 2018 Press release - Regulatory Agenda for Targovax Capital Markets Day 15 October 2018, in Oslo, Norway
October 11, 2018 Press release - Regulatory Targovax Key Opinion Leader Symposium on Oncolytic Viruses in New York City today, 11 October, 2018
October 4, 2018 Press release - Regulatory Targovax to host Capital Markets Day 15 October 2018, in Oslo, Norway
October 1, 2018 Press release - Regulatory Targovax presented ONCOS-102 poster at 13th International Adenovirus Meeting
September 27, 2018 Press release - Regulatory Targovax announces interim results from Phase I trial of ONCOS-102 in checkpoint inhibitor refractory melanoma
September 27, 2018 Press release - Regulatory Targovax to Host Key Opinion Leader Symposium on Oncolytic Viruses in New York City, 11 October 2018
September 13, 2018 Press release - Regulatory Targovax strengthens management team with the appointment of Torbjørn Furuseth as CFO; Erik Digman Wiklund to become CBO
August 23, 2018 Press release - Regulatory Targovax ASA: Second quarter and first half year 2018 results
July 12, 2018 Press release - Regulatory Targovax and SOTIO announce first patient dosed in Phase I/II combination trial of ONCOS-102 with DCVAC
June 19, 2018 Press release - Regulatory Targovax granted EU Patent for mutant-RAS neoantigen platform 2nd generation product TG02
June 11, 2018 Press release - Regulatory Targovax strengthens focus on ONCOS oncolytic virus development program
May 24, 2018 Press release - Regulatory Targovax strengthens 2-year survival rate in resected pancreatic cancer with TG01
May 2, 2018 Press release - Regulatory Targovax announces early signal of efficacy in ONCOS-102 trial in mesothelioma
April 12, 2018 Press release - Regulatory Targovax strengthens Board of Directors with the appointment of Catherine Wheeler
February 7, 2018 Press release - Regulatory Targovax announces completion of safety lead-in and preliminary immune activation data in ONCOS-102 trial in mesothelioma
January 8, 2018 Press release - Regulatory Targovax announces the appointment of Michael Bogenstaetter as Chief Business Officer
January 4, 2018 Press release - Regulatory Targovax announces that ONCOS-102 generates immune activation in checkpoint inhibitor refractory melanoma patients
